

# Plant therapeutic proteases: chemical aspects, applications and pharmaceutical formulations

P. F. Ferreira, R. E. Silva-López\*

Department of Natural Products, Institute of Pharmaceuticals Technology,

Fiocruz, Av. Brasil 4365, CEP: 21045-900, Rio de Janeiro, RJ, Brazil

## Authors' contributions

This work was carried out in collaboration by the two authors. Author RESL designed the study. Both authors searched the literature, wrote the text and approved the final version of the manuscript.

## Abstract

**Background:** Plants are important sources of therapeutic proteases with expressive activity, stability, specificity, and efficiency. These proteases are employed at low concentrations and produce lesser side effects. They have complex tridimensional structures whose maintenance is a challenge, requiring specific conditions to guarantee the biological and pharmacological activities of these compounds.

**Aims:** To conduct a literature review about plant therapeutic proteases, their principal biochemical aspects, potentials and clinical applications, and main pharmaceutical formulations.

**Material and methods:** The present study consisted of a bibliographic survey of the major plant therapeutic proteases. An investigation was performed in the PUBMED, SciELO, ScienceDirect and Academic Google databases using the keywords plant enzymes, therapeutic protease, immobilization, formulation.

**Results:** Some plant therapeutic proteases, such as papain and bromelain, are employed to treat many diseases and conditions, but the complexity of their structures is an important limitation of their uses. Thus, the structure and activities of their formulations need to be stabilized and protected against degradation, with improved pharmacokinetics, a prolonged time of action, reduced toxic effects, and proper direction towards their therapeutic target. Nanotechnology has made it possible to manufacture drug carriers such as polymeric nano- and microparticles, hydrogels, dendrimers and liposomes which are able to increase their efficacy and clinical applicability, as well as patient compliance. Sustainability initiatives that use Green Chemistry together with nanobiotechnology have managed to reduce the risks of toxicity to organisms and the environment. Green synthesis uses lower concentrations of metal ions, water-soluble, biocompatible and non-toxic compounds, as well as seeking energy efficiency and using renewable sources of raw materials.

**Conclusions:** Investigations about new formulations of plant therapeutic proteases using biodegradable and biocompatible polymers is of great biomedical interest because

they generate less toxic new biopharmaceuticals, in addition to protecting and stabilizing the enzymatic structure.

**Keywords:** plant enzymes, therapeutic protease, immobilization, formulation.

## 1. Introduction

Plants have been used as medicine since ancient times. They are sources of a wide variety of biologically active molecules whose chemical identification and pharmacological properties have been extensively investigated <sup>[1]</sup>. Plant metabolites from secondary metabolism have been most extensively studied and characterized since they are expressed in response to variations in environmental conditions and as a defense against microorganisms, insects and predators. However, their primary metabolites, such as proteins, have been poorly studied and their pharmacological potential is underexplored, while their major function is considered to be the provision of amino acids for human and animal diets <sup>[2]</sup>. Plant proteases are the proteins most extensively employed for pharmacological purposes <sup>[3]</sup>. They catalyze protein and peptide hydrolysis reactions, regulating the physiology of organisms. Due to their selectivity and efficacy, they are of paramount importance in the treatment of numerous diseases <sup>[4]</sup>. However, their therapeutic potential and clinical applications are often affected by difficulties related to administration, biochemical instability, pharmacological activity and reaching the therapeutic targets. In recent years, different ways of encapsulating and attaching a polymer to proteases using suitable carriers have been studied in order to permit oral administration, avoiding the aforementioned problems and thus preserving their therapeutic effect <sup>[5]</sup>.

Recent investigations in the nanotechnology field have developed nanostructured release systems that modulate drug release within the therapeutic interval and for a prolonged time in a single dose <sup>[6]</sup>. This review aims to draw attention to plant proteases as important therapeutic agents since they have expressive enzymatic activity and stability and are relatively easy and inexpensive to obtain from natural resources. We also comment about formulation strategies that will maintain their pharmacological activity.

## 2. Methodology

The present study consisted of a bibliographic survey of the types of therapeutic proteases found in plants, their biochemical aspects, applications and possible formulations as biological medicines. From 2019 to 2021, an investigation was performed in the PUBMED, SciELO, ScienceDirect and Academic Google databases using the keywords plant enzymes, therapeutic protease, immobilization, formulation.

We selected a total of 104 publications (articles and books) reporting scientific research on the enzymatic and pharmacological activity of proteases found in plants and

79 their possible formulations involving aggregation to nanoparticles, hydrogels, liposomes  
80 or dendrimers. The approaches used involved the period from 1957 to 2021.

### 82 **3. Literature Review**

#### 83 **3.1 Proteases**

84 Proteases, peptidases or proteolytic enzymes irreversibly cleave the peptide bonds  
85 in proteins and in peptides, originating proteins, peptides or free amino acids of smaller  
86 molecular mass <sup>[7]</sup>. They are found in all organisms, organs, and organelles, and about  
87 2% of an organism's genome has sequences that code for proteases. They have  
88 enormous chemical, kinetic and structural diversity which adapts them to their wide  
89 range of functions and to the different environments where they catalyze <sup>[7,8,9]</sup>.

90 These enzymes are classified according to their cleavage sites: exopeptidases (EC  
91 3.4.11-19), when they act on peptide bonds at the N- or C-terminal of polypeptide  
92 chains, and endopeptidases (EC 3.4.21-99), when they act inside the chains. However,  
93 proteases are mainly classified according to the catalytic amino acid of the active site  
94 involved in catalysis. The hydroxyl group of serine (EC 3.4.21) and threonine (EC 3.4.25)  
95 and the sulfhydryl group of cysteine proteases (EC 3.4.22) are nucleophilic agents, while  
96 activated water is the nucleophilic agent in aspartic (EC 3.4.23), glutamic (EC 3.4.19)  
97 and metalloproteases (EC 3.4.24), whose catalytic amino acid residues are serine,  
98 threonine, cysteine, aspartic acid, glutamic acid and an ion for enzymatic catalysis <sup>[10]</sup>.  
99 The breaking of peptide bonds is classically mediated by hydrolases (EC 3.4), but it can  
100 also be mediated by carbon-nitrogen lyases (EC 4.3.2) called asparagin peptidases,  
101 which represent the seventh group of proteases <sup>[9]</sup>.

102 Proteases are further classified according to the pH range where the enzymatic  
103 activity is maximum because the ionization of catalytic amino acids influences the  
104 catalysis. In addition, optimum pH values also suggest the cell compartment where the  
105 protease catalyzes. Aspartic proteases preferentially act in the acidic pH range; cysteine  
106 at slightly acidic pHs and serine and metalloproteases at neutral to alkaline pHs <sup>[11]</sup>.

107 The MEROPS database classifies proteases and protease inhibitors into clans and  
108 families according to the percentage of similarity between the amino acid sequences  
109 (primary structure) and the active site of the proteases (peptidase unit) or the inhibitory  
110 domain of proteases. Each family is identified by a letter that represents the catalytic  
111 type of each protease: aspartic (A), cysteine (C), glutamic (G), metallo (M), asparagine  
112 (N), mixed (P), serine (S), threonine (T), and unknown (U) <sup>[9]</sup>.

113 Proteases are primarily related to protein digestion for amino acid assimilation.  
114 However, these enzymes are also essential for physiological responses such as: blood  
115 clotting, fibrinolysis, extracellular matrix remodeling, activation and inactivation of  
116 biologically active molecules, protein folding and degradation, apoptosis, and  
117 complement cascade, among others <sup>[12,13]</sup>. Therefore, they participate in cancer  
118 invasiveness, necrosis, and tissue damage in response to pathogenic microorganisms <sup>[14]</sup>.

119 Plant peptidases express many types of proteases that are crucial for growth,  
120 development, defense against pathogens, senescence, apoptosis, xylem formation,  
121 tissue and organ differentiation, seed maturation, mobilization of protein reserves,  
122 germination, cell division, reproduction, adaptation to environmental changes,  
123 metabolism control, and many other functions <sup>[13,15,16,17]</sup>. Their potential biotechnological  
124 and pharmacological applications have been investigated, since plant proteases have  
125 important activity and stability in response to temperature, pH and ionic strength  
126 variations of the environment, which are essential requirements for their applications  
127 <sup>[16,17]</sup>. Therefore, the identification and understanding of the action of plant proteases  
128 permits the use of these enzymes as valuable therapeutic agents for the development of  
129 new biopharmaceuticals with greater specificity and less toxicity for the treatment of  
130 various pathologies and conditions, which are intractable with small synthetic drugs <sup>[18]</sup>.

### 132 **3.2 Biotechnological use of proteases**

133 Biotechnology refers to the methodology sets that use living organisms or their  
134 parts for the production or modification of products or services, and for the genetic  
135 improvement of plants and animals, applied to industry, health and the environment. It is  
136 a multidisciplinary area of knowledge that involves Biochemistry, Molecular Biology,  
137 Microbiology, Chemical Engineering, and other sciences. Biotechnology is responsible  
138 for the development and production of a wide variety of products such as foods, textiles,  
139 antibiotics, and biopharmaceuticals commonly containing proteins with functions as  
140 enzymes, hormones, antibodies, growth factors, and vaccines <sup>[19,20]</sup>.

141 According to the Allied Market Research report, the global enzyme market was  
142 about 7,082 million dollars in 2017, and is projected to reach \$10,519 million in 2024.  
143 This growth will result in gains because enzymes are very specific, fast and nontoxic,  
144 properties that minimize the cost and reduce the time of the manufacturing process <sup>[21,22]</sup>.  
145 However, restrictions related to the chemical properties of enzymes, such as low  
146 stability, have been a challenging factor for their use. These challenges have been  
147 solved with the use of enzyme-based technologies, resulting in gains associated with the  
148 production of food and beverages, animal feed, biopharmaceuticals, and diagnostics  
149 <sup>[22,23]</sup>. Proteases represent 50% of the macromolecules employed in biotechnological  
150 processes <sup>[21]</sup>. Furthermore, it is important to emphasize that they need to have essential  
151 attributes such as expressive proteolytic activity, high specificity, and important stability  
152 at high temperatures and in the presence of chemical agents <sup>[17]</sup>.

### 154 **3.3 Therapeutic proteases**

155 Proteolytic enzymes constitute a growing class of biopharmaceuticals, with the  
156 approval of more than 30 therapeutic proteases by the Food and Drug Administration,  
157 USA (FDA), in addition to the new proteases that are still in the clinical study phase <sup>[24]</sup>.

158 Therapeutic proteases are enzymes employed for the treatment of diseases,  
159 surgical procedures, and diagnosis. They must have purity according to the  
160 pharmaceutical form used, specificity, low antigenicity (avoidance of immunological  
161 reactions) and stability under physiological conditions. Proteases have been successfully  
162 used for the treatment of hemophilia, traumatic bleeding, thrombosis, heart attack,  
163 cerebrovascular ischemia, vitreomacular adhesion, cystic fibrosis, muscular dystrophy,  
164 celiac disease, septicemia, digestive failure (pancreatic and intestinal), debridement and  
165 wound healing, cardiovascular surgery, and catheterization <sup>[18,24]</sup>. Intravenous  
166 biopharmaceuticals are heterologous proteins involving a more suitable delivery of  
167 protein obtaining by minimizing the risks of contamination and immunological reactions in  
168 patients when compared to proteases extracted from human or animal tissues, which are  
169 generally used in topical or oral medications. Heterologous expression, although very  
170 expensive, provides greater amounts of proteins in relation to its extraction from natural  
171 sources, whose purification yield is, in general, low and variable due to their low  
172 concentrations in biological tissues and fluids <sup>[17]</sup>. However, some commercial proteases  
173 are abundantly obtained from natural resources such as collagenase (EC 3.4.24.3) from  
174 *Clostridium histolyticum* which is secreted into the culture medium <sup>[25]</sup>, trypsin (EC  
175 3.4.21.4) obtained from bovine pancreas <sup>[26]</sup>, pepsin (EC 3.4.23.1) extracted from the  
176 stomach of ruminants, and papain (EC 3.4.22.2) obtained from the latex of *Carica  
177 papaya* <sup>[27]</sup>.

178 The use of proteases in medicine dates back to the late 19th century. Crude  
179 porcine pancreatic enzyme preparations were employed to treat gastrointestinal  
180 disorders. Before the first World War, Takamine®, produced by the fungus *Aspergillus*  
181 *oryzae* and containing proteases and amylases, was developed in order to manage  
182 digestive dysfunctions <sup>[28]</sup>. The use of therapeutic proteases is the only strategy for the  
183 treatment of hemostasis disorders such as haemophilia and thrombosis. Urokinase, also  
184 known as urokinase-type plasminogen activator (uPA), originally isolated from  
185 human urine, was approved by the FDA in 1978 for the treatment of thrombosis, while  
186 coagulation factor IX, originally isolated from human plasma, was approved in 1986 for  
187 the management of hemophilia B. Later, other proteases such as thrombin, obtained  
188 from bovine plasma and enzymes extracted from the pancreas, such as trypsin,  
189 chymotrypsin, elastase and carboxypeptidases, were approved for commercialization  
190 and used with great success for various purposes. Topical thrombin formulations are  
191 used in bandages to accelerate the healing of large wounds and burns, while capsules  
192 containing pancreatic proteases are administered orally for the treatment of digestive  
193 disorders. In 1987, the first recombinant protease, tissue plasminogen activator (tPa),  
194 was approved for the treatment of thrombosis and marketed as alteplase®, reteplase®  
195 and tenecteplase® <sup>[18]</sup>.

### 197 **3.4 Therapeutic plant proteases**

Plants express various enzymes with significant protease activity on different substrates of biological interest. In addition, these proteases are stable at high temperatures and in the presence of chemical agents. As previously mentioned, such features are essential for their medicinal and biotechnological use<sup>[29]</sup>. For these reasons, their structures, physicochemical and kinetic features, as well as their potential applications, have been extensively studied<sup>[30]</sup>.

Plant therapeutic proteases are not heterologous proteins, because they are obtained directly from plant organs or latex, and they can be extracted without affecting plant viability, unless they are obtained from the roots. Their preparations are not pathogenic for animals since they do not contain infectious agents that cause diseases in vertebrates. In addition, the methodology for obtaining them is relatively simple, easy and of low cost<sup>[31,32]</sup>. These proteases are widely used as therapeutic enzymes in the treatment of many diseases and conditions and they also participate in various biotechnological processes<sup>[30,33]</sup> (Table 1). It is unquestionable that these plant proteases have a wide pharmacological potential, justifying their use in different pharmaceutical formulations.

**Table 1** - Examples of plant proteases and some medicinal and biotechnological uses (Adapted from Silva-López & Gonçalves, 2019)<sup>[30]</sup>.

Protease	Origin	Medicinal uses	Biotechnological uses
Actinidin	Kiwi ( <i>Actinidia deliciosa</i> )	Diabetic foot ulcer, protein digestion and constipation	Dietary supplement and meat tenderization.
Bromelain	Pineapple ( <i>Ananas comosus</i> )	Thrombosis, arthritis, wounds, cancers, asthma, bronchitis, sinusitis, analgesia, edema, vascular, cardiac and inflammatory diseases	Meat tenderization, bread production, tooth whitening.
Cardosin	Cardoon ( <i>Cynara cardunculus</i> )	No investigated medicinal effect	Milk clot and cheese manufacturing.
Cucumisin	Melon ( <i>Cucumis melo</i> )	Thrombosis	Meat tenderization, collagen hydrolysis to obtain gelatin, milk clot and synthesis of dipeptides.
Ficin	Fig ( <i>Ficus</i> genus)	Vermifuge	Peptide synthesis and antibody fragmentation.
Oryzasin	Rice ( <i>Oryza sativa</i> )	No investigated medicinal effect	Milk clot
Papain	Papaya ( <i>Carica papaya</i> )	Edema, sinusitis, digestive disorders, caries removal, wound healing, infections, cancer	Detergent, leather and meat tenderization, peptide synthesis, antibody fragmentation, beverage production, reduction of food allergy
Phytasin	Barley ( <i>Hordeum vulgare</i> )	No investigated medicinal effect	Milk clot
Zingipain	Ginger ( <i>Zingiber officinale</i> )	Antiproliferative agent in animal models of cancer/	No biotechnological uses investigated

224 There are many other plant proteases that have been investigated due to their  
225 biotechnological and therapeutical potential and promising results have been observed  
226 [34,35]. However, few plant proteases are commercialized and used as therapeutic agents  
227 or for biotechnological purposes. These are papain, bromelain and ficin, and some  
228 biochemical and pharmacological aspects of these proteases will be addressed in this  
229 manuscript.

### 231 **Papain**

232 Papain is a cysteine protease (EC 3.4.22.2) mainly extracted from *Carica papaya*  
233 latex (papaya papaya) and *Vasconcellea cundinamarcensis* (sugar papaya), but it can  
234 also be found in many parts of these plants. It is a 23 kDa single polypeptide chain  
235 endopeptidase [36] and was the second protein to be crystallized (1968) and the first  
236 cysteine protease with an elucidated 3D structure (1984). Papain is a model of the  
237 cysteine protease family and, according to MEROPS [37, 38], it belongs to the papain  
238 superfamily and C1A subfamily

239 This enzyme is stable at high temperatures and has many medicinal uses such as:  
240 treating edema, sinusitis, leaky bowel syndrome, gluten intolerance, digestive disorders  
241 and removing cavities [39], with antibacterial [40], anthelmintic [41] and antifungal [42]  
242 activities. This protease has an anti-angiogenic effect, preventing the proliferation,  
243 invasion and migration of tumors, as well as inducing apoptosis in human tumor cell lines  
244 [43]. It has been employed in tissue debridement to stimulate the healing of ulcers since it  
245 hydrolyzes necrotic tissues, aiding tissue regeneration. In addition, it stimulates the  
246 production of cytokines that repair cells and slow down the growth of microorganisms [29].

247 In papaya, papain leads to latex clotting, forming a physical barrier as a primary  
248 step in the defense mechanism [44]. Although it is the most studied cysteine protease,  
249 there are few studies on its therapeutic applications and no reports on its toxicological  
250 data. The available studies, however, provide a model for the study of cysteine  
251 proteases that are used in the treatment of many diseases [45].

### 253 **Bromelain**

254 Bromelain is an aqueous extract rich in cysteine proteases obtained from the  
255 stems and fruits of Bromeliaceae family species, with pineapple (*Ananas comosus*, *A.*  
256 *sativus*, *Bromelia ananas*) being the species most frequently studied. This extract  
257 contains four proteases with molecular masses between 20 and 31 kDa that belong to  
258 the papain superfamily: stem bromelain (EC 3.4.22.32), comosaine and fruit bromelain  
259 (EC 3.4.22.33), and ananaine (EC 3.4.22.31). All of these enzymes have bromelain  
260 protease activity and exhibit expressive stability at high temperatures. The extract is  
261 prepared from pineapple juice by centrifugation, ultrafiltration and lyophilization and  
262 produces a yellowish powder which is applied by food, beverage, cosmetic, textile and  
263 pharmaceutical industries [46].

Pineapple (chemically known since 1876) is used as a medicinal plant in several cultures and its medicinal properties are attributed to bromelain. Due to its complex composition, this protease has many pharmacological properties and has been used to treat rheumatoid arthritis, thrombophlebitis, wounds, cancer, angina, bronchitis, sinusitis, osteoarthritis, surgical trauma, and pyelonephritis, as well as to improve the absorption of certain drugs. This extract importantly alleviates pain and edema and shortens healing time compared to conventional treatments [47,48]. Bromelain induces the reduction of inflammatory and pain mediators, acting as an anti-inflammatory agent in many conditions, attenuating asthma [49], rheumatoid arthritis and osteoarthritis [50]

The course of intestinal infections is affected by oral treatment with bromelain, which degrades the adhesion receptor of bacteria to the intestinal mucosa [51]. In addition, bromelain has anthelmintic and antifungal activities [47].

Debridement is the clearance of dead, infected, senescent and/or devitalized tissues from a wound that interfere with healing. This procedure converts a chronic wound to an acute one, reducing bacterial growth. Bromelain degrades necrotic tissue, regulates cell maturation and multiplication, stimulates collagen and elastin synthesis, and removes perivascular fibrin. It also hydrolyzes the damaged components of the extracellular matrix, releasing growth and angiogenic factors sequestered in this matrix and activating chemokines and cytokines. Bromelain debridement accelerates blood perfusion recovery, improves inflammation, increases fibroblast and smooth muscle cell chemotaxis, and is more efficient than painful surgical debridement. Thus, the patients are not exposed to anesthesia, bleeding and infections. Enzymatic debridement reduces wound healing time, morbidity and mortality in severely burned patients. Bromelain has very low toxicity and is not carcinogenic or teratogenic [32].

## **Ficin**

Ficus species produce latex from laticiferous cells. Latex is a complex, sticky, milky liquid that is excreted in response to injury to protect the plant from invading pathogens, as mentioned for papain. Protease fractions from latex of Ficus species predominantly contain cysteine proteases, but serine and aspartic proteases are also found. The latex of the fig tree, *Ficus carica*, has a high activity of the cysteine protease known as ficin (EC 3.4.22.3), which consists of six isoforms, A, B, C, D1, D2 and E, with single-polypeptides chains of about 24 kDa [52]

Ficin can be used in many types of industries (Table 1). The latex of some Ficus species is traditionally used as an anthelmintic agent, although it has not been submitted to clinical or toxicological trials [53]. Ficin also has intense collagenolytic and chitinolytic activity, the latter giving the plant resistance against fungi and insects [54].

All therapeutic proteases, and every medicine, need to be biologically active to perform their pharmacological functions, and this is only possible if the chemical

structure is maintained. Therefore, the development of specific formulations that maintain their structures and activities guarantees their therapeutic uses.

### 3.5 Pharmaceutical formulation of proteases

Pharmaceutical formulations are intended to ensure the stability, solubility and biological and pharmacological activities of a drug <sup>[55]</sup>. Historically, the first medicines date back to Galen (129-199 A.D.), who discovered and used natural medicines in their pure forms. Their descriptions include various substances of natural origin, as well as formulas and methods of manipulation, proposing preparations of plant substances by mixing or fusing the individual components. In 1948, after World War II, Alexander Fleming discovered penicillin, an antibiotic that has saved many lives <sup>[56,57]</sup>. In the 1980s, recombinant DNA technology led to an increase in the number of recombinant proteins with high therapeutic potential, especially enzymes <sup>[58]</sup>.

The use of proteases as therapeutic molecules is crucial for the treatment of many diseases due to their high specificity and activity. It is important to emphasize that these enzymes are used at much lower concentrations than those of low molecular weight synthetic drugs in order to achieve similar pharmacological effects, besides, they cause fewer adverse effects. Despite the current biotechnological advances, the use of proteases as drugs is still a great challenge since they have complex and unstable structures, high molecular weights and low permeability through the biological membranes of target cells <sup>[59]</sup>. Therefore, their transport and release in the body are difficult and they may lose their activity, which directly depends on the maintenance of their structure. In addition, their absorption is limited, and they generally have a short half-life in the body due to enzymatic degradation at the administration site or during the journey to the action site <sup>[60,61]</sup>. Conventional methods of administration are designed to rapidly release biologically active molecules with therapeutic potential. Generally, water-soluble diluent systems are used to favor the drug's solubility. However, keeping plasma concentration levels within the therapeutic range is still one of the biggest challenges <sup>[62]</sup>.

Therapeutic proteases are usually administered in the form of aqueous solutions or suspensions via the parenteral route (subcutaneous or intravenous) which provide greater bioavailability <sup>[63,64]</sup>. However, the parenteral route has some disadvantages such as the risk of contamination, pain and discomfort for the patient during application, the need for sterile preparations, and difficulties in self-administration. These limitations of drug administration have inspired the investigation of several alternative routes for the delivery of biopharmaceuticals, such as pulmonary, nasal, oral, transdermal, vaginal, rectal and ocular routes, which have been explored in order to increase patient adherence to treatments. Most of the studies about the pulmonary route of administration have used aerosol formulations that have been very effective for the treatment of respiratory inflammation and other lung disorders <sup>[65]</sup>. This pathway represents a possibility for systemic and non-invasive release of proteases <sup>[66]</sup>. Another

343 therapeutic route is the transdermal one, which uses adhesives and is a painless  
344 alternative to injections. However, this route is still little used and only delivers  
345 hydrophobic and low molecular weight drugs, which is not the case for enzymes <sup>[67]</sup>. The  
346 oral administration of drugs is easier, cheaper and better accepted by the patients.  
347 However, the oral administration of therapeutic proteases is very limited due to the rapid  
348 degradation of these enzymes caused by the wide variation in pH of digestive proteases  
349 of the gastrointestinal tract. Furthermore, these therapeutic proteases cannot permeate  
350 the intestinal membrane because a receptor coupled to a transporter or carrier is  
351 required for absorption. Each of these routes offer advantages and limitations, and  
352 formulations have been developed to minimize these limitations <sup>[68]</sup>.


353 Some formulation strategies can increase the bioavailability of these drugs without  
354 a drastic change in their structure and activity, thus improving stability, efficacy and  
355 specificity, decreasing immunogenicity, and ensuring good pharmacokinetics <sup>[69]</sup>.  
356 Pegylation, which is a chemical conjugation with polyethylene glycol (PEG), is widely  
357 used to prolong the residence time of enzymes in the blood, in addition to promoting  
358 their site-specific release <sup>[70]</sup>. Although it can decrease the protein immunogenicity and  
359 increase its solubility, the main benefit of pegylation is the reduction in the frequency of  
360 doses due to their longer half-life in the body's circulation <sup>[67]</sup>.

### 361 **3.6 Polymeric drug delivery systems**

362 The development of a drug delivery system must take into account its incorporation  
363 capacity, the possibility of site-specific release, the interaction with biological molecules,  
364 the degradation rate, the accumulation of the drug in organs, its toxicity and the  
365 possibility of production on a large scale. The physicochemical stability of enzymes also  
366 needs to be evaluated when choosing the method of formulation preparation, since it can  
367 be affected by environmental factors that are part of the production process, such as pH,  
368 temperature, high pressure, organic solvents, metal ions, and agitation, among other  
369 factors that can lead to loss of protein structure and activity <sup>[6]</sup>.


370 Polymeric vehicles, besides having specific degradation characteristics, should  
371 also protect the therapeutic enzyme from proteolysis. This can be achieved by  
372 incorporating polymers, specifically cross-linked acrylic polymers such as Carbopol®  
373 (carbomer) and polycarbophil. Due to the rapid and high swelling and dispersion of these  
374 polymers in aqueous solutions, they should be incorporated into other polymers of a  
375 hydrophobic nature in order to control the erosion rate and minimize their effect on the  
376 diffusion barrier <sup>[71,72]</sup>. Different polymeric systems have been extensively studied for  
377 enzyme transport, the most important being micro- or nanocapsules, micro- or  
378 nanospheres, hydrogels, dendrimers, and liposomes (Figure 1). They are characterized  
379 by a high degree of innovation and versatility and can improve pharmacokinetics by  
380 offering site-specific prolonged release, reduction of adverse effects and increased  
381 bioavailability of biopharmaceuticals <sup>[58]</sup>. The process for obtaining these particles  
382

depends on the physicochemical characteristics of an enzyme such as size, distribution and morphology, which, in turn, determine their behavior regarding the encapsulation and release of the drug [73].



**Figure 1** – Schematic presentation of the structure of some polymeric drug delivery systems: micro or nanocapsule (A), micro or nanosphere (B), hydrogel (C), dendrimer, (D) and liposome (E). (Adapted from Zhang et al, 2013) [74].

These polymeric drug delivery systems can be classified according to their size and dispersion. Particles 1 to 1000  $\mu\text{m}$  in diameter are classified as microcapsules or microspheres. Colloidal particles 10 and 1000 nm in diameter, in which the drug can be dissolved, encapsulated or dispersed, are nanocapsules or nanospheres (Figure 1A and 1B) [74]. Micro or nanocapsules are spherical structures with a well-defined core where the drug is located inside an aqueous or oily cavity surrounded by a polymeric membrane (Figure 2A). On the other hand, the structure of micro or nanospheres consists of a single matrix in which the drug is dispersed and encapsulated by a biodegradable polymer, forming a homogeneous mixture (Figure 2B) [75]. The small diameter of nanoparticles offers advantages over microparticles such as greater ease in crossing the intestinal epithelium compared to microparticles [76].



**Figure 2** – Schematic presentation of the structure of micro- or nanocapsules (A), micro- or nanospheres (B) and a polymeric hydrogel (C) (Adapted from Melo, Cunha & Fialho, 2012) [58].

All of these structures are composed of biodegradable polymers such as polyesters, polyanhydrides and polysaccharides that normally are not toxic and are easily eliminated from the body. Polymers used in nanoparticle formulations are the same as those for microparticle preparations, and are widely used in the controlled administration of drugs with extended release, including synthetic polyesters such as

420 polylactic acid, copolymers of lactic and glycolic acids and poly( $\epsilon$ -caprolactone). Natural  
421 polymers, on the other hand, include some proteins such as albumin, collagen and  
422 gelatin and polysaccharides such as chitosan [77,78].

423 Hydrogel is an important system employed for drug delivery (Figure 1C) defined as  
424 a three-dimensional structure of highly porous polymer chains, which can be easily  
425 modeled by controlling the number of cross-links, and can absorb large amounts of water  
426 or biological fluid (Figure 2C). It is sensitive to environmental variations such as pH,  
427 electric field, ionic strength, and the presence of certain molecules, which can induce  
428 structural changes in the hydrogel. Its porosity allows the release of drugs at a rate that  
429 is dependent on the diffusion coefficient of molecules from the polymeric system to the  
430 therapeutic target [79,80]. These systems can be prepared in a wide variety of physical  
431 forms, including deposit formulations, microparticles, nanoparticles, coatings, and films  
432 [81]. Kashyap et al. (2007) developed a biodegradable hydrogel consisting of glucose  
433 linked to chitosan chains with high sensitivity to pH variation, which induces insulin  
434 release in response to hyperglycemia [82].

435 Dendrimer is a nanosystem used in drug transport (Figure 2D) consisting of highly  
436 branched molecules of: nanometric size; specific shape and structure; layers or  
437 generations composed of repeating units and radially connected to the starter core and  
438 functionalized end groups; hydrophobic core with hydrophilic periphery; and low  
439 polydispersity. They are closely similar to human proteins such as insulin, hemoglobin  
440 and cytochrome C, and are inert in the human body, with low toxicity and  
441 immunogenicity [83,84]. Drug payloads can be trapped in dendrimer layers through the  
442 generation of non-covalent complexes or bonded to their surface through covalent  
443 bonds. Covalently constructed dendritic macromolecules have the advantage of having  
444 more control of drug release and can be designed to limit drug release into the systemic  
445 circulation, triggering release under specific conditions. The type of bond depends on the  
446 physicochemical characteristics of a protein and the functional groups present in  
447 dendrimers. For example, hydrophobic molecules can bind to the nucleus or  
448 polyamidoamine branches, facilitating their transport through tissues and cells due to  
449 their large number of surface groups that can covalently bind to a wide variety of  
450 molecules [84,85].


451 Liposome is another type of polymeric system used for drug transport and delivery  
452 (Figure 1E). It consists of lipid bilayers separated by an aqueous medium, with a  
453 spherical structure with amphiphilic molecules and can encapsulate hydrophilic  
454 substances in the aqueous core and lipophilic substances in the interior of lipid bilayers  
455 [86]. The fluidity of lipid bilayers allows structural flexibility, eases the interaction with cell  
456 membranes, and has the ability to incorporate water and fat-soluble compounds.  
457 Furthermore, lipid bilayers are biodegradable, biocompatible and non-immunogenic [87].  
458 Conventional liposomes are composed of phospholipids with negative or positive  
459 charges that prevent vesicle aggregation, and of cholesterol that increases their stability

in suspensions. *In vivo* long-lasting liposomes are obtained by different methods, including coating the liposome surface with natural hydrophilic components such as monosialoganglioside (GM1) and phosphatidylinositol, or synthetic hydrophilic polymers, specifically PEG. The hydrophilic surface layer of these polymers increases the circulation time and prevents association with opsonins (antigen-bound molecules that facilitate phagocytosis) in plasma<sup>[88]</sup>.

PEGs inhibit molecular recognition and uptake by cells of the mononuclear phagocytic system<sup>[92]</sup>. Modification of the liposome surface with PEG can circumvent these problems because of the increased stability<sup>[87]</sup>. The most commonly used lipids in liposome formulations are phosphatidylcholines, phosphatidylserine, phosphatidylglycerol and sphingomyelins, which form a stable bilayer in aqueous solution. Phosphatidylcholines are the compounds most frequently used in liposome formulation studies because of their great stability against variations in pH or salt concentration in the medium due to both positive and negative charges<sup>[89]</sup>.

### 3.7 Methods for Incorporating Proteins and Peptides

The preparation of polymeric systems depends on the efficiency of the methodologies used for enzyme incorporation, which allow the modulation of structures, compositions and physiological properties of these proteins<sup>[90,91]</sup>. The choice of a preparation methodology will depend on the polymer and the solubility of the biopharmaceuticals to be encapsulated. The methods most frequently employed for the incorporation of peptides and proteins are multiple emulsion, phase separation and spray drying<sup>[92]</sup>.



**Figure 3** – Nanotechnology scheme for incorporating proteins and/or peptides into polymeric drug delivery systems (Adapted from Mundargi et. al., 2008) <sup>[92]</sup>.

The first step consists of obtaining a water-in-oil emulsion by dispersing an aqueous solution with the protein or peptide to be encapsulated in an organic solvent, already containing the dissolved polymer. With this method, the solution is emulsified with a large amount of aqueous medium to form a water-in-oil-in-water multiple emulsion, where the protein is in the internal aqueous phase and the polymer in the organic (or oily) phase. Polymeric systems are further formed by solvent removal (Figure 3). In the phase separation method, a non-solvent is added under stirring to the water-in-oil emulsion, where the protein is in the internal aqueous phase and the polymer in the organic (or oily) phase, inducing agglomeration of protein molecules and transforming the stable colloidal system into immiscible solutions of different concentrations <sup>[61]</sup>.

Spray drying (SD) is performed from a water/oil emulsion with polymeric particles loaded with therapeutic proteases, which must be homogeneous to allow greater precision and dose-by-dose reproducibility (Figure 3). For this purpose, SD is used to obtain polymeric particles loaded with therapeutic enzymes in the form of dry powder. It is a drying method for obtaining "post-dry" from a liquid phase which is widely used in the food, pharmaceutical, polymer and chemical industries. In the case of encapsulation of therapeutic proteases into spheres or capsules, the dry powder can be obtained from a solution, suspension or emulsion. Proteases are best preserved in the "post-dry" form, which increases stability during storage by eliminating water] thus, SD is also used as a method of preservation. This is a reproducible and fast technique, which can be scaled up and produce stable particles without the need for lyophilization. SD is a continuous process divided into four stages: atomization, mixing of droplets with drying gas, evaporation, and product separation. Its limitation is the solvent evaporation that does not allow the production of particles on a large scale <sup>[93]</sup>.

A physicochemical method of double emulsion is the most suitable for the nanoencapsulation of hydrophylic proteins. It is conceptually simple, and consists of the preparation of a primary water/oil emulsion by sonication of an aqueous solution containing the protein and an organic polymer solution. This emulsion constitutes the internal phase of the second emulsion, also prepared by sonication, whose external phase is an aqueous solution with a surfactant. The preparation of nanoparticle formulations by this methodology requires the presence of an emulsifying agent to stabilize the dispersed phase into a water/oil/water multiple emulsion. The emulsifying agent, in this case, is required to prevent aggregation and coalescence of particles <sup>[94]</sup>.


The development of new protein formulation techniques, mainly for plant proteases, in the form of micro/nanoparticles has increased the stability, efficiency and specificity of these biopharmaceuticals for medicinal use, and has decreased their toxicity.

547 The newest strategy for protein formulation from nanoparticles has been  
548 investigated using natural materials from plant extracts, bacteria, fungi, yeasts, algae,  
549 and biomolecules (enzymes and polysaccharides), which provide differentiated  
550 characteristics such as protection, reduced toxicity and stability of the formulation of  
551 nanoparticles, in addition to a high yield and low production cost <sup>[95,96]</sup>. Sustainability  
552 initiatives that use green chemistry to improve and/or protect our global environment are  
553 becoming focal issues in many fields of research <sup>[94]</sup>, and the use of various biological  
554 entities has received considerable attention in the field of nanobiotechnology <sup>[98]</sup>. In order  
555 to reduce the risks of toxicity to living organisms and the environment, green synthesis  
556 uses lower concentrations of metal ions and water-soluble, biocompatible, non-toxic  
557 compounds <sup>[99,100]</sup>.

558 The principles of green chemistry are fundamental for the implementation of  
559 sustainable processes for environment preservation, and they are: economy of atoms;  
560 synthesis of less toxic products, as well as solvents and residues used in the process;  
561 search for energy efficiency; use of renewable sources of raw material; avoiding the  
562 formation of derivatives; catalysis; real-time analytics for pollution prevention; intrinsically  
563 safe chemicals for accident prevention <sup>[101]</sup>. The use of extracts from different parts of  
564 plants such as leaves, stems, roots, seeds, and fruits, and plant biomass, play an  
565 important role in these processes <sup>[102,101]</sup>.

566 The green chemistry method can provide a wide variety of types, sizes and shapes  
567 of nanoparticles, and as the growth phase length increases, the nanoparticles aggregate  
568 to form nanospheres, nanotubes, nanoprisms, nanohexahedra and a variety of other  
569 irregularly shaped nanoparticles. In the formation phase, these nanoparticles acquire the  
570 most favorable conformation from an energetic point of view, and this process is strongly  
571 influenced by the stabilizing capacity of plant extracts. The metal ion reduction process  
572 for the formation of nanoparticles is affected by the nature of the extract that contains  
573 active biomolecules in different combinations and concentrations, by the reaction mixture  
574 pH, temperature, reaction time, concentration and by the electrochemical potential of a  
575 metal ion <sup>[100]</sup>. The first step is mixing an aqueous solution of a metallic salt with a water-  
576 based extract. Next, the reduction of this metal solution converts metal ions from their  
577 mono, bi or trivalent oxidation states to zero valence states and the nucleation is  
578 initiated. In the nucleation phase, there is a reduction of metallic ions as well as the  
579 nucleation of reduced metallic atoms due to the electrostatic interactions between the  
580 positive charges of metallic ions and the negative charges of the carboxylic groups of the  
581 plant protease. Then, during the growth phase the small adjacent nanoparticles  
582 spontaneously fuse into larger particles, a process accompanied by increased  
583 thermodynamic stability of the nanoparticles, i.e., the reduction of ions is initiated by the  
584 components of biological materials, favoring the generation of the neutral metal (M<sup>0</sup>) that  
585 will agglomerate and trigger a phenomenon called nucleation. The biomolecules of the

extract act as covering agents to coat and stabilize the nanoparticles. The last step is the formation of metallic nanoparticles that will determine the final shape (Figure 4) [103].



**Figure 4** Steps of formation of metallic nanoparticles (Adapted from Toledo, 2021) [103].

Other studies have shown the efficiency of these types of formulations, such as the synthesis of silver nanoparticles and the use of a propolis extract and dragon blood sap with antimicrobial action [97], suggesting their application in hospital infections, or the aqueous extract of *Brosimum gaudichaudii* leaves in the application of an electrochemical nanobiosensor [104].

Thus, green chemistry has many advantages over the traditional method in the production of nanoparticles such as the use of an aqueous plant extract acting as a stabilizing and reducing agent during their formation. Its aqueous-based synthesis process is an ecological, direct and simple method that does not require specialized equipment [103].

#### 4. Conclusion

Therapeutic plant proteases have gained an important place in the treatment of various diseases and conditions, because they are specific, have great catalytic power, high stability and low acquisition cost. Their pharmaceutical formulations will depend on the administration routes, and the most used are the topical and the parenteral. In both types of formulations, plant proteases need to be immobilized or conjugated to a polymer that guarantees their structure and function. Many polymers have been used for pharmaceutical purposes due to their biodegradable structure, non-toxicity and easy to eliminate by the body. The most used is PEG, as it prolongs the half-life of proteases in the blood, promotes their site-specific release, reduces the protein immunogenicity, increases the solubility of proteases and reduces the frequency of doses. For topical formulation, the hydrogel systems are very good strategies, as they are easy to apply to the skin surface, biocompatibles with low interfacial tension with biological fluids and

tissues, they allow the active compound to penetrate deep into the skin regions and, they do not cause pain and damage to the mucosa or the blood vessels and no risk of infection, resulting in high patient compliance and tolerance. In the case of parenteral formulations, nanoparticles have the most suitable polymeric system for the protection of plant proteases, because they comprise characteristics applied to the controlled release of drugs and proteins in specific places in the body, as well as their small diameter will offer an advantage when permeating through the body. An in-depth literature review allowed us to conclude that polymeric nanoparticles, hydrogels, liposomes and dendrimers are excellent protease transporters protecting them against general degradation.

#### **CONSENT**

Not applicable.

#### **ETHICAL APPROVAL**

Not applicable.

#### **Declaration of competing interest**

The authors declare that there was no conflict of interest.

#### **Acknowledgments**

The authors are grateful to Farmanguinhos/Fiocruz.

#### **References**

- [1]. Henriques SR, Ferreira JWS, Muniz MP, Albuquerque UP. Adaptive memory and evolution of the human naturalistic mind: Insights from the use of medicinal plants. *PLoS One*. 2019;14(3):1-15. DOI: 10.1371/journal.pone.0214300.
- [2]. Rehman HM, Cooper JW, Lam HM, Yang SH. Legume biofortification is an underexploited strategy for combatting hidden hunger. *Plant Cell Environ*. 2019;42(1): 52-70. DOI: 10.1111/pce.13368.
- [3]. Turunen P, Rowan AE, Blank K. Single-enzyme kinetics with fluorogenic substrates: lessons learnt and future directions. *FEBS Lett*. 2014; 588(19):3553-63. DOI: 10.1016/j.febslet.2014.06.021.
- [4]. Chauhan VM, Zhang H, Dalby PA, Aylott JW. Advancements in the co-formulation of biologic therapeutics. *J Control Release*. 2020; 327:397-405. DOI: 10.1016/j.jconrel.2020.08.013.
- [5]. Botelho SM. Novas estratégias de administração de proteínas e peptídeos. Coimbra. 2014. <http://hdl.handle.net/10316/80572>.
- [6]. Prado FK. Desenvolvimento de método analítico para quantificação de antineoplásico em sistemas de liberação controlada de fármacos. São Paulo. 2019. <https://repositorio.usp.br/item/002954153>.
- [7]. Vizovišek M, Vidmar R, Drag M, Fonović M, Salvesen GS, Turk B. Protease specificity: Towards *in vivo* imaging applications and biomarker Discovery. *Trends in Biochem Sci*. 2018; 43(10):829-44. DOI: 10.1016/j.tibs.2018.07.003.
- [8]. Bond JS. Proteases: History, discovery, and roles in health and disease. *J Biol Chem*. 2019; 294(5):1643-51. DOI: 10.1074/jbc.TM118.004156.

- 677 [9]. Rawlings ND, Barrett AJ, Thomas PD, Huang X, Bateman A, Finn RD. The  
678 MEROPS database of proteolytic enzymes, their substrates and inhibitors in 2017 and a  
679 comparison with peptidases in the PANTHER database. *Nucleic Acids Res.*  
680 2018;46(D1):D624–32. DOI: 10.1093/nar/gkx1134.
- 681 [10]. Li Q, Yi L, Marek P, Iverson BL. Commercial proteases: Present and future.  
682 *FEBS Lett.* 2013; 587(8):1155–63. DOI: 10.1016/j.febslet.2012.12.019.
- 683 [11]. Silva-López RE. Immunocytochemistry of proteases in the study of *Leishmania*  
684 physiology and host-parasite interaction in applications of immunocytochemistry In:  
685 Dehghani H, editor. *Applications of immunocytochemistry*, InTech, Rijeka. 2012; 267–  
686 96. DOI: 10.5772/32954.
- 687 [12]. Mandujano-González V, Villa-Tanaca L, Anducho-Reyes MA, Mercado-Flores Y.  
688 Secreted fungal aspartic proteases: A review. *Rev Iberoam Micol.* 2016; 33(2):76-82.  
689 DOI: 10.1016/j.riam.2015.10.003.
- 690 [13]. Baker PJ, Numata K. Polymerization of peptide polymers for biomaterials  
691 applications. *Polymer Science.* IntechOpen, 2013. DOI: 10.5772/46141.
- 692 [14]. McCauley JA, Rudd MT. Hepatitis C virus NS3/4a protease inhibitors. *Curr Opin*  
693 *Pharmacol.* 2016; 30:84-92. DOI: 10.1016/j.coph.2016.07.015.
- 694 [15]. Van der Hoorn RAL, Jones JDG. The plant proteolytic machinery and its role in  
695 defence. *Curr Opin Plant Biol.* 2004; 7(4):400-7. DOI: 10.1016/j.pbi.2004.04.003.
- 696 [16]. Van der Hoorn RAL. Plant proteases: From phenotypes to molecular  
697 mechanisms. *Annu Rev Plant Biol.* 2008; 59:191–223.  
698 DOI: 10.1146/annurev.arplant.59.032607.092835.
- 699 [17]. Kurepa J, Wang S, Li Y, Smalle J. Proteasome regulation, plant growth and stress  
700 tolerance. *Plant Signal Behav.* 2009; 4 (10):924–27. DOI: 10.4161/psb.4.10.9469.
- 701 [18]. Craik CS, Page MJ, Madison EL. Proteases as therapeutics. *Biochem.* 2011;  
702 435(1):1–16. DOI: 10.1042/BJ20100965.
- 703 [19]. Schwaminger SP, Fraga-García P, Eigenfeld M, Becker TM, Berensmeier S.  
704 Magnetic separation in bioprocessing beyond the analytical scale: from biotechnology  
705 to the food industry. *Front Bioeng Biotechnol.* 2019; 7:233.  
706 DOI: 10.3389/fbioe.2019.00233
- 707 [20]. Gavrilescu M, Chisti Y. Biotechnology-a sustainable alternative for chemical  
708 industry. *Biotechnol Adv.* 2005; 23(7-8):471-99.  
709 DOI: 10.1016/j.biotechadv.2005.03.004.
- 710 [21]. de Souza PM, Bittencourt MLA, Caprara CC, de Freitas M, de Almeida RPC,  
711 Silveira D, et al. A biotechnology perspective of fungal proteases. *Braz J Microbiol.*  
712 2015; 46(2):337-46. DOI: 10.1590/S1517-838246220140359.
- 713 [22]. Oliveira LG, Mantovani SM. Transformações biológicas: contribuições e  
714 perspectivas. *Quim. Nova.* 2009; 32(3):742-56. DOI: 10.1590/S0100-  
715 40422009000300018.
- 716 [23]. Chapman J, Ismail AE, Dinu CZ. Industrial applications of enzymes: recent  
717 advances, techniques, and outlooks. *Catalysts.* 2018; 8:238.  
718 DOI:10.3390/CATAL8060238.
- 719 [24]. Vellard M. The enzyme as drug: application of enzymes as pharmaceuticals. *Curr*  
720 *Opin Biotechnol.* 2003; 14(4):444-50. DOI: 10.1016/s0958-1669(03)00092-2.
- 721 [25]. Raheem AA, Johnson M, Ralph D, Garaffa G. Collagenase *Clostridium*  
722 *histolyticum*: a novel medical treatment for Peyronie's disease. *Minerva Urol Nefrol.*  
723 2018; 70(4):380-85. DOI: 10.23736/S0393-2249.18.03118-1.
- 724 [26]. Kido H, Takahashi E, Kimoto T. Role of host trypsin-type serine proteases and  
725 influenza virus-cytokine-trypsin cycle in influenza viral pathogenesis. *Pathogenesis-*  
726  
727

- 728 based therapeutic options. *Biochimie.* 2019; 166:203-13.  
729 DOI: 10.1016/j.biochi.2019.09.006.
- 730 [27]. Leite AP, de Oliveira BGRB, Soares MF, Barrocas DLR. Use and effectiveness of  
731 papain in the wound healing process: a systematic review. *Rev Gaucha Enferm.*  
732 2012; 33(3):198-207. DOI: 10.1590/s1983-14472012000300026.
- 733 [28]. Sato K, Egami F. Studies on ribonucleases in takadiastase. *J Biochem.* 1957;  
734 44(11):753-67.
- 735 [29]. Pacheco JS, Silva-López RE. Study of the proteolytic activity of the tropical legume  
736 *Crotalaria spectabilis*. *Z Naturforsch C J Biosci.* 2012; 67(9-10):495–509.  
737 DOI: 10.1515/znc-2012-9-1008.
- 738
- 739 [30]. Silva-López RE, Gonçalves RN. Therapeutic proteases from plants:  
740 biopharmaceuticals with multiple applications. *J Appl Biotechnol Bioeng.* 2019;  
741 6(2):101–9. DOI:10.15406/jabb.2019.06.00180.
- 742 [31]. Menou A, Duitman JW, Crestani B. The impaired proteases and anti-proteases  
743 balance in idiopathic pulmonary fibrosis. *Matrix Biol.* 2018; 68-69:382-403.  
744 DOI: 10.1016/j.matbio.2018.03.001.
- 745 [32]. Silva-López, RE. Debridement applications of bromelain: a complex of cysteine  
746 proteases from pineapple. *Adv Biotechnol Microbiol.* 2017; 3(5): 124-6. ISSN: 2474-  
747 7637.
- 748 [33]. Feijoo-Siota L, Villa T G. Native and biotechnologically engineered plant  
749 proteases with industrial applications. *Food Bioprocess Technol.* 2011; 4:1066–88.  
750 DOI:10.1007/s11947-010-0431-4.
- 751 [34]. Silva MZR, Oliveira JPB, Ramos MV, Farias DF, de Sá CA, Ribeiro JAC, et al.  
752 Biotechnological potential of a cysteine protease (CpCP3) from *Calotropis procera*  
753 latex for cheesemaking. *Food Chem.* 2020; 307:125574.  
754 DOI: 10.1016/j.foodchem.2019.125574.
- 755
- 756 [34]. Siritapetawee J, Khunkaewla P, Thumanu K. Roles of a protease from *Euphorbia*  
757 *resinifera* latex in human anticoagulant and antithrombotic activities. *Chem Biol Interact.*  
758 2020; 329:109223. DOI: 10.1016/j.cbi.2020.109223.
- 759
- 760 [36]. Storer AC, Ménard R. Papain. *Handbook of Proteolytic Enzymes.* 2013; 2: 1858-61.  
761 DOI: 10.1016/B978-0-12-382219-2.00418-X.
- 762
- 763 [37]. Novinec M, Lenarčič B. Papain-like peptidases: structure, function, and evolution.  
764 *Biomol Concepts.* 2013; 4(3):287–308. DOI: 10.1515/bmc-2012-0054.
- 765 [38]. Rawlings ND, Barrett AJ, Finn R. Twenty years of the MEROPS database of  
766 proteolytic enzymes, their substrates and inhibitors. *Nucleic Acids Res.* 2016;  
767 44(D1):D343–50. DOI: 10.1093/nar/gkv1118.
- 768 [39]. Amri E, Mamboya F. Papain, a plant enzyme of biological importance: a review.  
769 *Am J Biochem Biotech.* 2012; 8(2):99–104. DOI: 10.3844/ajbb.2012.99.104.
- 770 [40]. Dos Anjos MM, Da Silva AA, De Pascoli IC, Mikcha JMG, Machinski M, Peralta  
771 RM et al. Antibacterial activity of papain and bromelain on *Alicyclobacillus* spp. *Int J*  
772 *Food Microbiol.* 2016; 216:121–26. DOI: 10.1016/j.ijfoodmicro.2015.10.007.
- 773 [41]. Moraes D, Levenhagen MA, Costa-Cruz JM, Costa-Netto AP, Rodrigues RM. *In*  
774 *vitro* efficacy of latex and purified papain from *Carica papaya* against *Strongyloides*  
775 *venezuelensis* eggs and larvae. *Rev Inst Med Trop.* 2017; 59:e7. DOI: 10.1590/S1678-  
776 9946201759007.
- 777 [42]. Mota VS, Turrini RNT, Poveda VB. Antimicrobial activity of *Eucalyptus globulus* oil,  
778 xylitol and papain: a pilot study. *Rev Esc Enferm USP.* 2015; 49(2):215–19.  
779 DOI: 10.1590/S0080-623420150000200005.

[43]. Müller A, Barat S, Chen X, Bui KC, Bozko P, Malek NP et al. Comparative study of antitumor effects of bromelain and papain in human cholangiocarcinoma cell lines. *Int J Oncol*. 2016; 48(5):2025-34. DOI: 10.3892/ijo.2016.3411.

[44]. Shindo T, Van de Hoorn RAL. Papain-like cysteine proteases: key players at molecular battlefields employed by both plants and their invaders. *Mol Plant Pathol*. 2008; 9(1):119–25. DOI:

[45]. Chen YY, Lu YH, Ma CH, Tao WW, Zhu JJ, Zhang X. A novel elastic liposome for skin delivery of papain and its application on hypertrophic scar. *Biomed Pharmacother*. 2017; 87:82–91. DOI: 10.1016/j.biopha.2016.12.076.

[46]. De Lencastre Novaes LC, Jozala AF, Lopes AM, Santos-Ebinuma VC, Mazzola PG, Pessoa Jr A. Stability, purification, and applications of bromelain: a review. *Biotechnol Prog*. 2016; 32(1):5–13. DOI: 10.1002/btpr.2190.

[47]. Taussig SJ, Batkin S. Bromelain, the enzyme complex of pineapple (*Ananas comosus*) and its clinical application. *J Ethnopharmacol*. 1988; 22(2):191–203. DOI: 10.1016/0378-8741(88)90127-4.

[48]. Bhui K, Prasad S, George J, Shukla Y. Bromelain inhibits COX-2 expression by blocking the activation of MAPK regulated NF-kappa B against skin tumor-initiation triggering mitochondrial death pathway. *Cancer Lett*. 2009; 282(2):167–76. DOI: 10.1016/j.canlet.2009.03.003.

[49]. Secor ER, Szczepanek SM, Castater CA, Adami AJ, Matson AP, Rafti ET et al. Bromelain inhibits allergic sensitization and murine asthma via modulation of dendritic cells. *Evid Based Complement Alternat Med*. 2013; 2013:702196. DOI: 10.1155/2013/702196.

[50]. Jayachandran S, Khobre P. Efficacy of bromelain along with trypsin, rutoside trihydrate enzymes and diclofenac sodium combination therapy for the treatment of TMJ Osteoarthritis - A randomised clinical trial. *J Clin Diagn Res*. 2017; 11(6):ZC09-ZC11. DOI: 10.7860/JCDR/2017/25771.9964.

[51]. Mynott TL, Guandalini S, Raimondi F, Fasano A. Bromelain prevents secretion caused by *Vibrio cholerae* and *Escherichia coli* enterotoxins in rabbit ileum *in vitro*. *Gastroenterology*. 1997; 113(1):175-84. DOI: 10.1016/s0016-5085(97)70093-3.

[52]. Baeyens-Volant D, Matagne A, El Mahyaoui R, Wattiez R, Azarkan M. A novel form of ficin from *Ficus carica* latex: purification and characterization. *Phytochem*. 2015; 117:54–67. DOI: 10.1016/j.phytochem.2015.05.019.

[53]. Shahidi S, Jamili S, Ghavam Mostafavi P, Rezaie S, Khorramizadeh M. Assessment of the inhibitory effects of ficin-hydrolyzed gelatin derived from squid (*Uroteuthis duvauceli*) on breast cancer cell lines and animal model. *Iran J Allergy Asthma Immunol*. 2018; 17(5):436-52. DOI: 10.18502/ijaai.v17i5.302.

[54]. Raskovic B, Lazic J, Polovic N. Characterisation of general proteolytic, milk clotting and antifungal activity of *Ficus carica* latex during fruit ripening. *J Sci Food Agric*. 2016; 96(2):576–82. DOI: 10.1002/jsfa.7126.

[55]. Storpirtis S, Gonçalves JE, Chiann C, Gai MN. Ciências farmacêuticas: Biofarmacotécnica. Rio de Janeiro: Ed. Guanabara Koogan, 2009.

[56]. Nasciutti PR. Desenvolvimento de novos fármacos. Goiás. 2012. [https://files.cercomp.ufg.br/weby/up/67/o/1%C2%B0\\_Semin%C3%A1rio\\_PRISCILLA\\_NASCIUTTI.pdf?1350665635](https://files.cercomp.ufg.br/weby/up/67/o/1%C2%B0_Semin%C3%A1rio_PRISCILLA_NASCIUTTI.pdf?1350665635).

[57]. Loyd V, Allen Jr, Nicholas GP, Howard CA. Formas Farmacêuticas e Sistemas de Liberação de Fármacos. 9ª edição, Ed. Artmed, 2013.

[58]. Melo CS, Cunha Jr AS, Fialho SL. Formas farmacêuticas poliméricas para a administração de peptídeos e proteínas terapêuticos. *Rev Ciênc Farm Básica Apl*. 2012; 33(4):469-77. ISSN 1808-4532.

- 831 [59]. McClements DJ. Encapsulation, protection, and delivery of bioactive proteins and  
832 peptides using nanoparticle and microparticle systems: A review. *Adv Colloid Interface*  
833 *Sci.* 2018; 253:1-22. DOI: 10.1016/j.cis.2018.02.002.
- 834 [60]. Almeida AJ, Souto E. Solid lipid nanoparticles as drug delivery systems for  
835 peptides and proteins. *Adv Drug Del Rev.* 2007; 59(6):478-90. DOI:  
836 10.1016/j.addr.2007.04.007.
- 837 [61]. Feitosa RC, Geraldés DC, de-Araújo BVL, Costa JSR, Oliveira-Nascimento L.  
838 Pharmacokinetic aspects of nanoparticle-in-matrix drug delivery systems for  
839 oral/buccal delivery. *Front Pharmacol.* 2019; 10:1057. DOI: 10.3389/fphar.2019.01057.
- 840 [62]. Bizerra A, Silva V. Sistemas de liberação controlada: Mecanismos e aplicações.  
841 *Revista Saúde e Meio Ambiente.* 2016; 3(2):1-12. ISSN: 2447-8822.
- 842 [63]. Moeller EH, Jorgensen L. Alternative routes of administration for systemic  
843 delivery of protein pharmaceuticals. *Drug Discov Today: Technol.* 2008; 5(2-3):e89-  
844 94. DOI: 10.1016/j.ddtec.2008.11.005.
- 845 [64]. Silva AC, Lopes CM, Lobo JMS, Amaral MH. Delivery systems for  
846 biopharmaceuticals. Part I: Nanoparticles and Microparticles. *Curr Pharm Biotechnol.*  
847 2015; 16(11):940-54. DOI: 10.2174/1389201016666150731112532.
- 848 [65]. Lin YW, Zhou QT, Hu Y, Onufrak NJ, Sun S, Wang J et al. Pulmonary  
849 pharmacokinetics of colistin following administration of dry powder aerosols in rats.  
850 *Antimicrob Agents Chemother.* 2017; 61(11):e00973-17. DOI: 10.1128/AAC.00973-17.
- 851 [66]. Steiner V, Öhlinger K, Corzo C, Salar-Behzadi S, Fröhlich E. Cytotoxicity  
852 screening of emulsifiers for pulmonary application of lipid nanoparticles. *Eur J Pharm*  
853 *Sci.* 2019; 136:104968. DOI: 10.1016/j.ejps.2019.104968.
- 854 [67]. Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering  
855 biopharmaceuticals: formulation and delivery strategies. *Nat Rev Drug Discov.* 2014;  
856 13(9):655-72. DOI: 10.1038/nrd4363.
- 857 [68]. Griffin BT, Guo J, Presas E, Donovan MD, Alonso MJ, O'Driscoll CM.  
858 Pharmacokinetic, pharmacodynamic and biodistribution following oral administration of  
859 nanocarriers containing peptide and protein drugs. *Adv Drug Deliv Rev.* 2016; 106(Pt  
860 B):367-80. DOI: 10.1016/j.addr.2016.06.006.
- 861 [69]. Muheem A, Shakeel F, Jahangir MA, Anwar M, Mallick N, Jain GK et al. A review  
862 on the strategies for oral delivery of proteins and peptides and their clinical  
863 perspectives. *Saudi Pharm J.* 2016; 24(4):413-28. DOI: 10.1016/j.jsps.2014.06.004.
- 864 [70]. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming  
865 biological barriers to drug delivery. *Nat Biotechnol.* 2015; 33(9):941-51.  
866 DOI: 10.1038/nbt.3330.
- 867 [71]. Bai JP, Chang LL, Guo JH. Effects of polyacrylic polymers on the luminal  
868 proteolysis of peptide drugs in the colon. *J Pharm Sci.* 1995; 84(11):1291-94.  
869 DOI: 10.1002/jps.2600841107.
- 870 [72]. Silva C, Ribeiro A, Ferreira D, Veiga F. Administração oral de peptídios e  
871 proteínas: Estratégias gerais para aumento da biodisponibilidade oral. *Rev.Bras.*  
872 *Cienc. Farm.* 2002; 38(2):125-140. DOI: 10.1590/S1516-93322002000200002.
- 873 [73]. Réus M, Carmignan F, Lemos Senna E, Machado de Campos A. Nanopartículas  
874 poliméricas na administração tópica ocular de fármacos. *Lat. Am J Pharm.* 2009;  
875 28(1):125-32. ISSN 0326-2383.
- 876 [74]. Zhang L, Wang S, Zhang M, Sun J. Nanocarriers for oral drug delivery. *J Drug*  
877 *Target.* 2013; 21(6):515-27. DOI: 10.3109/1061186X.2013.789033.
- 878 [75]. Wang L, Liu Y, Zhang W, Chen X, Yang T, Ma G. Microspheres and  
879 microcapsules for protein delivery: Strategies of drug activity retention. *Curr Pharm*  
880 *Des.* 2013; 19(35):6340-52. DOI: 10.2174/1381612811319350010.

- [76]. Reis CP, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. *Nanomedicine*. 2006; 2(2):53-65. DOI: 10.1016/j.nano.2006.04.009.
- [77]. Lu XY, Wu DC, Li ZJ, Chen GQ. Polymer nanoparticles. *Prog Mol Biol Transl Sci*. 2011; 104:299-323. DOI: 10.1016/B978-0-12-416020-0.00007-3.
- [78]. Qodratnama R, Serino LP, Cox HC, Qutachi O, White LJ. Formulations for modulation of protein release from large-size PLGA microparticles for tissue engineering. *Mater Sci Eng C Mater Biol Appl*. 2015; 47:230-6. DOI: 10.1016/j.msec.2014.11.003.
- [79]. Liu Y, Lu W, Wang J, Zhang X, Zhang H, Wang X, et al. Controlled delivery of recombinant hirudin based on thermo-sensitive Pluronic® F127 hydrogel for subcutaneous administration: In vitro and in vivo characterization. *J Control Release*. 2007; 117(3):387-95. DOI: 10.1016/j.jconrel.2006.11.024.
- [80]. Sokker HH, Abdel Ghaffar AM, Gad YH, Aly AS. Synthesis and characterization of hydrogels based on grafted chitosan for the controlled drug release. *Carbohyd Polym*. 2009; 75(2):222-29. DOI: 10.1016/j.carbpol.2008.06.015.
- [81]. Hoare TR, Kohane DS. Hydrogels in drug delivery: progress and challenges. *Polymer*. 2008; 49(8):1993-2007. DOI: 10.1016/j.polymer.2008.01.027.
- [82]. Kashyap N, Viswanad B, Sharma G, Bhardwaj V, Ramarao P, Kumar MNV. Design and evaluation of biodegradable, biosensitive *in situ* gelling system for pulsatile delivery of insulin. *Biomaterials*. 2007; 28(11):2051-60. DOI: 10.1016/j.biomaterials.2007.01.007.
- [83]. Nanjwade BK, Bechra HM, Derkar GK, Manvi FV, Nanjwade VK. Dendrimers: emerging polymers for drug-delivery systems. *Eur J Pharm Sci*. 2009; 38(3):185-96. DOI: 10.1016/j.ejps.2009.07.008.
- [84]. Pimenta LFC. Influência de dendrímeros e da iontoforese na penetração da protoporfirina IX em tumores cutâneos. Ribeirão Preto. 2013. DOI: 10.11606/D.60.2013.tde-18122013-093754.
- [85]. Onoue S, Yamada S, Chan HK. Nanodrugs: pharmacokinetics and safety. *Int J Nanomedicine*. 2014; 9:1025-37. DOI: 10.2147/IJN.S38378.
- [86]. D'Abreu DP. Sistemas de nanopartículas híbridas para veiculação de DNA. Lisboa. 2017. <http://hdl.handle.net/10451/36115>.
- [87]. Coutinho JA. Nanopartículas na entrega eficaz e segura de fármacos ao cérebro por via nasal. Experiência Profissionalizante na vertente de Farmácia Comunitária, Hospitalar e Investigação. Covilhã. 2015. [https://ubibiorum.ubi.pt/bitstream/10400.6/5324/1/4265\\_8200.pdf](https://ubibiorum.ubi.pt/bitstream/10400.6/5324/1/4265_8200.pdf).
- [88]. Madigan MT, Martinko JM, Dunlap PV, Clark DP. *Microbiologia de Brock*. 14ª edição. Porto Alegre: Artmed. 2016; 1160.
- [89]. Batista CM, Carvalho CMB, Magalhães NSS. Lipossomas e aplicações terapêuticas: Estado da arte. *Braz J Pharma Sci*. 2007; 43(2):167-79. DOI: 10.1590/S1516-93322007000200003.
- [90]. Dés Rieux A, Fievez V, Garinot M, Schneider Y, Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. *J Control Release*. 2006; 116(1):1-27. DOI: 10.1016/j.jconrel.2006.08.013.
- [91]. Grabnar PA, Kristl J. The manufacturing techniques of drug-loaded polymeric nanoparticles from preformed polymers. *J Microencapsul*. 2011; 28(4):323-35. DOI: 10.3109/02652048.2011.569763.
- [92]. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. *J Control Release*. 2008; 125(3):193-209. DOI: 10.1016/j.jconrel.2007.09.013.

- 932 [93]. Ré MI. Formulating Drug Delivery Systems by Spray Drying. *Drying Technol.*  
933 2006; 24(4):433-46. DOI:10.1080/07373930600611877.
- 934 [94]. Mishra DK, Ashish KJ, Prateek KJ. Review on Various Techniques of  
935 Microencapsulation. *Int J Pharma Chem Sci.* 2013; 2(2):962-77. ISSN: 2277-5005.
- 936 [95]. Lee KX, Shameli K, Mohamad SE, Yew YP, Mohamed-Isa ED, Yap HY et al. Bio-  
937 mediated synthesis and characterisation of silver nanocarrier, and its potent anticancer  
938 action. *Nanomaterials (Basel).* 2019; 9(10):1423-41. DOI: 10.3390/nano9101423.
- 939 [96]. Mathur P, Jha S, Ramteke S, Jain NK. Pharmaceutical aspects of silver  
940 nanoparticles. *Artif Cells Nanomed Biotechnol.* 2018; 46(sup1):115-26.  
941 DOI: 10.1080/21691401.2017.1414825.
- 942 [97]. Freitas, I. Síntese Verde para obtenção de Nanopartículas de Prata a partir de  
943 Extratos Naturais. Rio de Janeiro. 2019; 60 p.  
944 <http://www.repositorio.poli.ufrj.br/monografias/monopoli10029768.pdf>.
- 945 [98]. Mane Gavade SJ, Nikam GH, Dhabbe RS, Sabale SR, Tamhankar BV, Mulik GN.  
946 Green synthesis of silver nanoparticles by using carambola fruit extract and their  
947 antibacterial activity. *Advances in Natural Sciences: Nanosci Nanotechnol.* 2015, 6(4):1-  
948 6. DOI: 10.1088/2043-6262/6/4/045015.
- 949 [99]. Oliveira GZS, Lopes CAP, Sousa MH, Silva LP. Synthesis of silver nanoparticles  
950 using aqueous extracts of *Pterodon emarginatus* leaves collected in the summer and  
951 winter seasons. *International Nano Letters.* 2019; 9:109-17. DOI:  
952 10.1007/s40089-019-0265-7.
- 953 [100]. Sena AEC, Ramos AL, Vianna-Faria FSED. Avaliação da síntese de  
954 nanopartículas de prata sob diferentes concentrações do extrato de *Copaiba multijuga*  
955 (Heine). *Scientia Naturalis.* 2019; 1(1):10-16. ISSN: 2596-1640.
- 956 [101]. Lopes JR. Síntese de nanopartículas de prata (NPsAg) em soluções aquosas de  
957 fibroína de seda e gelatina. Campinas. 2017, 115p.  
958 <http://repositorio.unicamp.br/jspui/handle/REPOSIP/322079>.
- 959 [102]. Kuppusamy P, Yusoff MM, Maniam GP, Govindan N. Biosynthesis of metallic  
960 nanoparticles using plant derivatives and their new avenues in pharmacological  
961 applications – An updated report. *Saudi Pharm Journal.* 2016; 24(4):473-84. DOI:  
962 10.1016/j.jsps.2014.11.013.
- 963 [103]. Toledo, ACO. Desenvolvimento, caracterização e avaliação das atividades  
964 biológicas de nanopartículas de prata e de ouro, obtidas por síntese verde, a partir do  
965 extrato aquoso das sementes de *Pterodon emarginatus* Vogel (Fabaceae) associadas à  
966 gentamicina e ao ácido hialurônico. Ponta Grossa. 2021; 169p.  
967 <http://tede2.uepg.br/jspui/handle/prefix/3339>.
- 968 [104]. Albernaz VL. Síntese verde de nanopartículas de prata com extrato aquoso de  
969 folhas de *Brosimum gaudichaudii*, caracterização físicoquímica, morfológica e suas  
970 aplicações no desenvolvimento de um nanobiossensor eletroquímico. Brasília, 2014.  
971 121p. <https://repositorio.unb.br/handle/10482/16467>.
- 972  
973  
974  
975  
976  
977  
978  
979  
980